SystImmune starts another first-line phase 3
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
HengRui presses on in HER3, despite Merck’s failure
The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.
World Lung 2025 – backing for Bristol’s pivotal HER3 conjugate moves
The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.
Bristol takes its bispecific conjugate into lung cancer
A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
Bristol goes pivotal with SystImmune-partnered conjugate
The first global pivotal trial will be in first-line triple-negative breast cancer.
Avenzo follows Bristol’s lead
The private group taps DualityBio for an EGFR x HER3 ADC.
An unfamiliar name goes after familiar targets
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
